Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Angelo H. Paredes"'
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0217263 (2019)
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that can lead to cirrhosis, liver transplant, and even hepatocellular carcinoma. While liver biopsy remains the reference standard for disease diagnosis, analytical and clinical developme
Externí odkaz:
https://doaj.org/article/d70a0ea59b034e4fb7487af2d289a4b9
Autor:
Denise Siqueira Vanni, Abhijit Chowdhury, Arun J. Sanyal, Mohammed S. Siddiqui, José Tadeu Stefano, Sherry Boyett, Claudia P. Oliveira, Angelo H. Paredes, Lawrence Serfaty
Publikováno v:
Hepatoma research. 6
To compare the phenotype of lean versus overweight (OW) and obese (OB) subjects with non-alcoholic fatty liver disease (NAFLD) across multiple continents.A retrospective study of histologically defined subjects from a single center each in France (Fr
Autor:
Stephen A Harrison, Andrea Dennis, Martine M Fiore, Matt D Kelly, Catherine J Kelly, Angelo H Paredes, Jennifer M Whitehead, Stefan Neubauer, Peter G Traber, Rajarshi Banerjee
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203054 (2018)
BACKGROUND:Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and l
Externí odkaz:
https://doaj.org/article/4a3e8be29d4749638ba6e15dc36714f4
Autor:
Rosco S. Gore, Anthony A. Cochet, James K. Aden, Angelo H. Paredes, John Magulick, Stephen A. Harrison, Peter C. Johnson
Publikováno v:
The Korean Journal of Gastroenterology. 78:161-167
Backgrounds/aims Nonalcoholic fatty liver disease (NAFLD) encompasses a range of diseases from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and has been linked to cardiovascular disease and sub-clinical cardiac remodeling. T
Autor:
Manal F. Abdelmalek, Margery A. Connelly, Stephen J. Rossi, Mary E. Rinella, Angelo H. Paredes, Stephen A. Harrison, Lei Ling, James F. Trotter, Mark J. Jaros, Alex M. DePaoli
Publikováno v:
Journal of Hepatology. 70:735-744
NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes
Autor:
Christopher J. Lisanti, Stefan Neubauer, Aymeric Labourdette, Samer Gawrieh, Valérie Paradis, Céline Fournier, Angelo H. Paredes, Véronique Miette, Ryan B. Schwope, Katherine M. Cebe, Naim Alkhouri, Pierre Bedossa, Stephen A. Harrison, Katharine Roberts, Jennifer Whitehead
Publikováno v:
Journal of hepatology. 75(2)
Background & Aims Large prospective studies to establish the prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptoma
Autor:
Kristin Nelson, Hsiao D. Lieu, Mildred Gottwald, James F. Trotter, Guy W. Neff, Nadege Gunn, Alex M. DePaoli, Sam E. Moussa, Ziad Younes, Andrew Yan, Mustafa R. Bashir, Angelo H. Paredes, Juan P. Frias, William C.G. Chang, Cynthia D. Guy, Stephen A. Harrison, Lei Ling, Anita Kohli
Publikováno v:
Gastroenterology. 160(1)
Background & Aims Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalco
Autor:
Stephen J. Rossi, Mary E. Rinella, Mark J. Jaros, Alex M. DePaoli, Marcelo Kugelmas, Stephen A. Harrison, Manal F. Abdelmalek, Hays Arnold, James F. Trotter, Mustafa R. Bashir, ing L, Angelo H. Paredes, Rohit Loomba
Publikováno v:
The Lancet. 391:1174-1185
Non-alcoholic steatohepatitis is a chronic liver disease characterised by the presence of hepatic steatosis, inflammation, and hepatocellular injury, for which no Food and Drug Administration (FDA)-approved treatment exists. FGF19 is a hormone that r
Publikováno v:
Cureus
Introduction Liver biopsy is the gold standard in diagnosing, staging and guiding clinical management in liver disease. There are currently no standard guidelines for liver biopsy recovery time. The aims of this project are to study the safety of a o